Ocular Adverse Effects in Atopic Dermatitis Patients Treated With Dupilumab: A Bibliometric Analysis

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin disorders. Dupilumab, the first targeted biological drug approved for the treatment of AD, has been widely used, along with increasing ocular adverse effects (AEs). To perform a bibliometric analysis of all the qualified lite...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in medicine Vol. 9; p. 802036
Main Authors Jia, Qian-Nan, Qiao, Ju, Fang, Kai, Zeng, Yue-Ping
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 03.03.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Atopic dermatitis (AD) is one of the most common chronic inflammatory skin disorders. Dupilumab, the first targeted biological drug approved for the treatment of AD, has been widely used, along with increasing ocular adverse effects (AEs). To perform a bibliometric analysis of all the qualified literature involving ocular AEs during the treatment of AD with dupilumab. Relevant studies were extracted from the Web of Science database and screened by researchers. The bibliographic analysis was performed using the VOSviewer. A total of 138 articles were enrolled in this study. The first study was published in 2016 by Oregon Health and Science University from the United States. The majority of publications were published in the past 3 years. published the highest number of articles. The United States was the country with the most publications. Sanofi (France) and Regeneron Pharmaceuticals (USA) were the leading organizations with the most contributions. Conjunctivitis was the most common ocular AE. The management of AD will continue to be the research hotspot and development trend in this area. The milestone research is the first article "Two Phase 3 Trials of Dupilumab vs. Placebo in Atopic Dermatitis" published in the . Most of the top 10 papers were mainly randomized, placebo-controlled phase 2 and phase 3 clinical trials and real-life large cohort studies. This study may help better understand ocular AEs in the dupilumab treatment of AD, and grasp the research trends and most influential topics in this field.
Bibliography:content type line 23
SourceType-Scholarly Journals-1
Edited by: Paolo Fogagnolo, University of Milan, Italy
This article was submitted to Ophthalmology, a section of the journal Frontiers in Medicine
Reviewed by: Serena Lembo, University of Salerno, Italy; Alvise Sernicola, University of Padua, Italy
ISSN:2296-858X
2296-858X
DOI:10.3389/fmed.2022.802036